This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vivus: FDA Panel Live Blog

Stocks in this article: VVUS ARNA OREX

WASHINGTON, D.C. ( TheStreet) -- Vivus (VVUS - Get Report): Take two.

A panel of outside experts impaneled by the U.S. Food and Drug Administration gathers today to review and pass judgment on Vivus' experimental obesity pill Qnexa. Once again, Qnexa's safety will be the most hotly debated topic.

At Vivus' first advisory panel last year, experts voted 10-6 to not recommend Qnexa's approval. While Qnexa helped patients lose about 10% of their body weight, the drug fell short due to safety concerns focused mostly on potential cardiovascular problems and a higher risk of cleft lips in children born to women who might get pregnant while prescribed Qnexa.

FDA followed the advice of its advisory panel and rejected Qnexa in October 2010. Vivus resubmitted Qnexa with longer-term data and analyses designed to ameliorate the agency's safety concerns.

In a second review of Qnexa posted Friday, FDA officials once again raised concerns about the drug's potential risk for birth defects and heart problems. But the agency also recognized Qnexa's ability to help patients lose weight and largely deferred overall judgment on the drug, choosing instead to allow the outside experts on the panel to weigh in with their recommendations.

Obesity has become an epidemic in the U.S., leading many public health officials to call for the FDA to approve a medicinal therapy to help people lose weight when exercise and diet are not enough. FDA, however, has taken a conservative stance when it comes to reviewing and regulating diet drugs. Some approved pills, like Abbott's (ABT) Meridia, have been pulled from the market at the FDA's request due to safety concerns. Last year, FDA also rejected three experimental obesity pills from Arena Pharmaceuticals (ARNA - Get Report), Orexigen Therapeutics (OREX - Get Report) and Vivus.

Vivus' Qnexa is comprised of two currently approved drugs -- phentermine, a generic weight loss drug, and topiramate, used to treat epilepsy and migraines.

Vivus shares closed Tuesday at $10.55. The stock will be halted Wednesday for the Qnexa advisory panel.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs